Infant Bacterial Therapeutics AB (publ) Delårsrapport 1 januari – 30 juni 2022
August 25, 2022 02:00 ET
|
Infant Bacterial Therapeutics AB
VD kommenterar Vårt utvecklingsprojekt IBP-9414 i klinisk fas III fortskrider väl, och vi har sett en ökning av rekryteringstakten. Vi har som jag tidigare nämnt arbetat med ett flertal aktiviteter...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement January 1-June 30, 2022
August 25, 2022 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO Our IBP-9414 clinical phase III development program is progressing well. We have seen an overall acceleration of recruitment rates and, as mentioned previously, have been...
Infant Bacterial Therapeutics AB utser Maria Ekdahl till CFO
June 30, 2022 11:00 ET
|
Infant Bacterial Therapeutics AB
Pressmeddelande 30 juni 2022 Infant Bacterial Therapeutics AB (publ) tillkännagav idag att Maria Ekdahl utsetts till Chief Financial Officer (CFO) och tillträder den 19 september 2022. Hon kommer att...
Infant Bacterial Therapeutics AB appoints Maria Ekdahl as CFO
June 30, 2022 11:00 ET
|
Infant Bacterial Therapeutics AB
Press Release June 30, 2022 Infant Bacterial Therapeutics AB (publ) announced today that Maria Ekdahl has been appointed Chief Financial Officer (CFO) effective September 19, 2022. She will be part...
Årsstämma i Infant Bacterial Therapeutics
May 04, 2022 10:00 ET
|
Infant Bacterial Therapeutics AB
På årsstämman i Infant Bacterial Therapeutics AB (publ) den 4 maj 2022 beslutades bland annat följande: fastställande av resultaträkningen och balansräkningen samt koncernresultaträkningen och...
Annual General Meeting of Infant Bacterial Therapeutics
May 04, 2022 10:00 ET
|
Infant Bacterial Therapeutics AB
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2022, among other things, the following was resolved: to adopt the income statement and balance sheet and the...
Kallelse till årsstämma i Infant Bacterial Therapeutics
April 05, 2022 14:00 ET
|
Infant Bacterial Therapeutics AB
Aktieägarna i Infant Bacterial Therapeutics AB (publ) kallas till årsstämma onsdagen den 4 maj 2022. Mot bakgrund av coronaviruset genomförs årsstämman genom förhandsröstning med stöd av tillfälliga...
Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics
April 05, 2022 14:00 ET
|
Infant Bacterial Therapeutics AB
Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Wednesday, May 4, 2022. In light of the coronavirus, the Annual General Meeting is conducted...
The Connection Study fortsätter efter planerad säkerhetsanalys av Data Monitoring Committee (DMC)
January 19, 2022 17:30 ET
|
Infant Bacterial Therapeutics AB
Den 30 september, 2021 meddelade Infant Bacterial Therapeutics (IBT) att företaget nått en viktig milstolpe i utvecklingen av IBP-9414, efter att ha rekryterat 600 för tidigt födda barn till The...
The Connection Study continues after pre-scheduled Data Monitoring Committee (DMC) review
January 19, 2022 17:30 ET
|
Infant Bacterial Therapeutics AB
On September 30, 2021 Infant Bacterial Therapeutics (IBT) announced that the company had reached a key milestone in the development of IBP-9414, after having recruited 600 premature infants to The...